Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study.
Elizabeth M E VerdegaalMonique K Van der KooijMarten VisserCaroline van der MinneLinda de BruinPauline MeijAnton Terwisscha van ScheltingaMarij J WeltersSaskia SantegoetsNoel F C C de MirandaInge RoozenGerrit Jan LiefersEllen KapiteijnSjoerd H Van der BurgPublished in: Journal for immunotherapy of cancer (2021)
This study demonstrates that ACT in combination with a mild IFNa preconditioning regimen can induce clinical benefit even in immunotherapy pretreated patients, although with lower success than in immunotherapy-naïve patients. ACT products comprising neoantigen reactivity may be more effective.